Omentin and apelin concentrations in relation to obesity, diabetes mellitus type two, and cardiovascular diseases in Egyptian population

Suresh S, Mahendra J. Multifactorial relationship of obesity and periodontal disease. J Clin Diagn Res. 2014;8:E01–3.

Al-husseini N, Arafat N, Mohammed E, Allam M. Effect of exercise training on adiponectin receptor expression and insulin resistance in mice fed a high fat diet. Am J Biochem Biotechnol. 2010;6:77–83.

Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013;339:172–7.

Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87:4–14.

Horwich T, Fonarow G. Glucose, obesity, metabolic syndrome, and diabetes: relevance to incidence of heart failure. J Am Coll Cardiol. 2010;55:283–93.

Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741–51.

Bays HE. Sick fat, metabolic disease and atherosclerosis. Am J Med. 2009;122:S26–37.

Bluher M. Adipose tissue dysfunction in obesity. Exp Clin Endocrinol Diabetes. 2009;117:241–50.

Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013;216:17–36.

Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Res Clin Pract. 2010;88:29–33.

Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease 2014; 12: 136–143.

Castan-Laurell I, Dray C, Knauf C, Kunduzova O, Valet P. Apelin, a promising target for type 2 diabetes treatment. Trends Endocrinol Metab. 2012;23:234–41.

Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2008;116:289–92.

Machura E, Szczepanska M, Ziora K, Ziora D, Swietochowska E. Evaluation of adipokines: apelin, visfatin, and resistin in children with atopic dermatitis. Mediat Inflamm. 2013;2013:119–27.

Manica-Cattani MF, Bittencourt L, Rocha MI, Algarve TD, Bodanese LC, Rech R. Association between interleukin-1 beta polymorphism and obesity. Mol Cell Endocrinol. 2010;314:84–9.

Pitkin SL. Modulation of the apelin system in heart failure and atherosclerosis in human. Br J Pharmacol. 2010;160:1785–95.

Mojtaba E, Shahram S, Heshmatolah P, Alireza Z. Pro-inflammatory cytokine interleukin-1 beta is associated with cardiovascular fitness in sedentary diabetic patients. J Biodivers Environ Sci. 2011;1:37–44.

Zhao G, Dharmadhikari G, Maedler K, Meyer-Hermann M. Possible role of interleukin-1β in type 2 diabetes onset and implications for anti-inflammatory therapy strategies. PLoS Comput Biol. 2014;10:100–8.

Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969;22:158–61.

Richmond W. Preparation and properties of a cholesterol oxidase from Nocardia sp. and its application to the enzymatic assay of total cholesterol in serum. Clin Chem. 1973;19:1350–6.

Siedel J, Hagele EO, Ziegenhorn J, Wahlefeld AW. Reagent for the enzymatic determination of serum total cholesterol with improved lipolytic efficiency. Clin Chem. 1983;29:1075–80.

Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J Lipid Res. 1970;11:583–95.

Hatch FT, Lees RS. Practical methods for plasma lipoprotein analysis. Adv Lipid Res. 1968;6:1–68.

Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Teacher DF, Turner RC. Homeostasis model assessment: insulin resistance and b cell function from fasting plasma glucose and insulin concentration in man. Diabetologia. 1985;28:412–9.

Chen CN, Li YSJ, Yeh YT, Lee PL. Synergistic roles of platelet-derived growth factor-BB and interleukin-1-beta in phenotypic modulation of human aortic smooth muscle cells. Proc Nat Acad Sci. 2006;103:2665–70.

Tan BK, Adya R, Farhatullah S, Lewandowski KC, O’Hare P, Lehnert H, et al. Omentin‐1, a novel adipokine, is decreased in overweight insulin resistant women with the polycystic ovary syndrome: ex vivo and in vivo regulation of omentin‐1 by insulin and glucose. Diabetes. 2008;57:801–8.

Principe A, Melgar-Lesmes P, Fernández-Varo G, Del Arbol LR, Ros J, Bernardi M, et al. The hepatic apelin system: a new therapeutic target for liver disease. Hepatology. 2008;48:1193–201.

Mirzaei K, Hossein-Nezhad A, Aslani S, Emamgholipour S, Karimi M, et al. Energy expenditure regulation via macrophage migration inhibitory factor (MIF) in obesity and in vitro anti-MIF effect of Alpinia officinarum Hance extraction. Endocr Pract. 2011;18:39–48.

Van RE, Jankowski CM, Gozansky WS, Schwartz RS, Kohrt WM. Lower-body adiposity and metabolic protection in postmenopausal women. J Clin Endocrinol Metab. 2005;90:4573–8.

Casper G, Coen DA. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci. 2005;109:143–59.

Caballero AE. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res. 2003;11:1278–89.

Arthur S, Ulf G. Dyslipidemia and risk of coronary heart disease: role of lifestyle approaches for its management. Am J Life Style Med. 2009;3:257–73.

Defilippi CR, de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494–502.

DeNardo D, Latz E. NLRP3 inflammasomes link inflammation and metabolic disease. Trends Immunol. 2011;32:373–9.

Ohashi K, Shibata R, Murohara T, Ouchi N. Role of anti-inflammatory adipokines in obesity related diseases. Trends Endocrinol Metab. 2014;25:348–55.

Shibata R, Ouchi N, Kikuchi R, Takahashi R, Takeshita K, Kataoka Y, et al. Circulating omentin is associated with coronary artery disease in men. Atherosclerosis. 2011;219:811–4.

Zhong X, Zhang HY, Tan H, Zhou Y, Liu FL, et al. Association of serum omentin-1 levels with coronary artery disease. Acta Pharmacol Sin. 2011;32:873–8.

Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W. Circulating omentin concentration increases after weight loss. Nutr Metab. 2010;7:27–38.

Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, et al. Identification of omentin as a novel depot specific adipokine in human adipose tissue: possible role in modulating insulin action. Am J Physiol Endocrinol Metab. 2006;290:1253–61.

Soriguer F, Garrido-Sanchez L, Garcia-Serrano S, Garcia-Almeida JM, Garcia-Arnes J. Apelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus. Obes Surg. 2009;19:1574–80.

Dray C, Debard C, Jager J, Disse E, Daviaud D, Martin P, et al. Apelin and APJ regulation in adipose tissue and skeletal muscle of type 2 diabetic mice and humans. Am J Physiol Endocrinol Metab. 2010;298:1161–9.

Higuchi K, Masaki T, Gotoh K, Chiba S, Katsuragi I, Tanaka K, et al. Apelin, an APJ receptor ligand, regulates body adiposity and favors the messenger ribonucleic acid expression of uncoupling proteins in mice. Endocrinology. 2007;148:2690–7.

Beltowski J. Apelin and visfatin: unique “beneficial” adipokines up-regulated in obesity. Med Sci Monit. 2006;12:112–9.

Attane C, Daviaud D, Dray C. Apelin stimulates glucose uptake but not lipolysis in human adipose tissue ex vivo. J Mol Endocrinol. 2011;46:21–8.

Garcia-Diaz D, Campion J, Milagro FI, Martinez JA. Adiposity dependent apelin gene expression: relationships with oxidative and inflammation markers. Mol Cell Biochem. 2007;305:87–94.